{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:55:55Z","timestamp":1768031755354,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"National Institute of health","award":["R01GM141279"],"award-info":[{"award-number":["R01GM141279"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40264-025-01545-6","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T04:11:06Z","timestamp":1745295066000},"page":"923-931","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Drug Similarity-Based Bayesian Method for Early Adverse Drug Event Detection"],"prefix":"10.1007","volume":"48","author":[{"given":"Yi","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuedi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqiao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4601-0779","authenticated-orcid":false,"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9148-5589","authenticated-orcid":false,"given":"Pengyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"issue":"10","key":"1545_CR1","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40264-017-0572-8","volume":"40","author":"A Santoro","year":"2017","unstructured":"Santoro A, Genov G, Spooner A, Raine J, Arlett P. Promoting and protecting public health: how the European Union Pharmacovigilance System Works. Drug Saf. 2017;40(10):855\u201369.","journal-title":"Drug Saf"},{"key":"1545_CR2","unstructured":"Food and Drug Administration (FDA). FDA Adverse Events Reporting System (FAERS) Public Dashboard. 2022 [cited 2022\/07\/05; Available from: https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee\/sheet\/7a47a261-d58b-4203-a8aa-6d3021737452\/state\/analysis. Accessed 12 Jan 2024."},{"issue":"6","key":"1545_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"1","key":"1545_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"1","key":"1545_CR5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/10543406.2013.736810","volume":"23","author":"L Huang","year":"2013","unstructured":"Huang L, Zalkikar J, Tiwari RC. Likelihood ratio test-based method for signal detection in drug classes using FDA\u2019s AERS database. J Biopharm Stat. 2013;23(1):178\u2013200.","journal-title":"J Biopharm Stat"},{"key":"1545_CR6","doi-asserted-by":"crossref","unstructured":"DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53(3).","DOI":"10.2307\/2686097"},{"issue":"7","key":"1545_CR7","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","volume":"30","author":"A Bate","year":"2007","unstructured":"Bate A. Bayesian confidence propagation neural network. Drug Saf. 2007;30(7):623\u20135.","journal-title":"Drug Saf"},{"issue":"125","key":"1545_CR8","doi-asserted-by":"publisher","first-page":"125ra31","DOI":"10.1126\/scitranslmed.3003377","volume":"4","author":"NP Tatonetti","year":"2012","unstructured":"Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012;4(125):125ra31.","journal-title":"Sci Transl Med."},{"issue":"8","key":"1545_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/psp4.12294","volume":"7","author":"P Zhang","year":"2018","unstructured":"Zhang P, Li M, Chiang CW, Wang L, Xiang Y, Cheng L, et al. Three-component mixture model-based adverse drug event signal detection for the adverse event reporting system. CPT Pharmacomet Syst Pharmacol. 2018;7(8):499\u2013506.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"13","key":"1545_CR10","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1002\/sim.3586","volume":"28","author":"I Ahmed","year":"2009","unstructured":"Ahmed I, Haramburu F, Fourrier-Reglat A, Thiessard F, Kreft-Jais C, Miremont-Salame G, et al. Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting. Stat Med. 2009;28(13):1774\u201392.","journal-title":"Stat Med"},{"issue":"4","key":"1545_CR11","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1021\/ci4000079","volume":"53","author":"F Cheng","year":"2013","unstructured":"Cheng F, Li W, Wang X, Zhou Y, Wu Z, Shen J, et al. Adverse drug events: database construction and in silico prediction. J Chem Inf Model. 2013;53(4):744\u201352.","journal-title":"J Chem Inf Model"},{"key":"1545_CR12","doi-asserted-by":"crossref","unstructured":"Kha QH, Le VH, Hung TNK, Nguyen NTK, Le NQK. Development and validation of an explainable machine learning-based prediction model for drug-food interactions from chemical structures. Sensors (Basel). 2023;23(8).","DOI":"10.3390\/s23083962"},{"issue":"12","key":"1545_CR13","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s43588-023-00555-7","volume":"3","author":"NQK Le","year":"2023","unstructured":"Le NQK. Predicting emerging drug interactions using GNNs. Nat Comput Sci. 2023;3(12):1007\u20138.","journal-title":"Nat Comput Sci."},{"issue":"5","key":"1545_CR14","doi-asserted-by":"publisher","first-page":"8809","DOI":"10.1038\/srep08809","volume":"6","author":"S Vilar","year":"2015","unstructured":"Vilar S, Tatonetti NP, Hripcsak G. 3D pharmacophoric similarity improves multi adverse drug event identification in pharmacovigilance. Sci Rep. 2015;6(5):8809.","journal-title":"Sci Rep"},{"key":"1545_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.773135","volume":"12","author":"X Ji","year":"2021","unstructured":"Ji X, Cui G, Xu C, Hou J, Zhang Y, Ren Y. Combining a pharmacological network model with a Bayesian signal detection algorithm to improve the detection of adverse drug events. Front Pharmacol. 2021;12: 773135.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1545_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12911-019-0999-1","volume":"19","author":"R Liu","year":"2019","unstructured":"Liu R, Zhang P. Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports. BMC Med Inform Decis Mak. 2019;19(1):279.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"2","key":"1545_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/wcms.1240","volume":"6","author":"AB Raies","year":"2016","unstructured":"Raies AB, Bajic VB. In silico toxicology: computational methods for the prediction of chemical toxicity. Wiley Interdiscip Rev Comput Mol Sci. 2016;6(2):147\u201372.","journal-title":"Wiley Interdiscip Rev Comput Mol Sci."},{"issue":"D1","key":"1545_CR18","doi-asserted-by":"publisher","first-page":"D1202","DOI":"10.1093\/nar\/gkv951","volume":"44","author":"S Kim","year":"2016","unstructured":"Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res. 2016;44(D1):D1202\u201313.","journal-title":"Nucleic Acids Res"},{"key":"1545_CR19","first-page":"547","volume":"37","author":"P Jaccard","year":"1901","unstructured":"Jaccard P. \u00c9tude comparative de la distribution florale dans une portion des Alpes et des Jura. Bulletin de la Soci\u00e9t\u00e9 vaudoise des sciences naturelles. 1901;37:547\u201379.","journal-title":"Bulletin de la Soci\u00e9t\u00e9 vaudoise des sciences naturelles."},{"issue":"D1","key":"1545_CR20","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","volume":"52","author":"C Knox","year":"2024","unstructured":"Knox C, Wilson M, Klinger CM, Franklin M, Oler E, Wilson A, et al. DrugBank 6.0: the DrugBank Knowledgebase for 2024. Nucleic Acids Res. 2024;52(D1):D1265\u201375.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"1545_CR21","doi-asserted-by":"publisher","first-page":"368504221109215","DOI":"10.1177\/00368504221109215","volume":"105","author":"S Kitsiranuwat","year":"2022","unstructured":"Kitsiranuwat S, Suratanee A, Plaimas K. Integration of various protein similarities using random forest technique to infer augmented drug-protein matrix for enhancing drug-disease association prediction. Sci Prog. 2022;105(3):368504221109215.","journal-title":"Sci Prog."},{"key":"1545_CR22","unstructured":"Pag\u00e8s H, Aboyoun P, Gentleman R, DebRoy S. Biostrings: Efficient manipulation of biological strings. 2024 [cited; Available from: https:\/\/bioconductor.org\/packages\/Biostrings. Accessed 12 Jan 2024."},{"key":"1545_CR23","first-page":"351","volume":"43","author":"WR Pearson","year":"2013","unstructured":"Pearson WR. Selecting the Right Similarity-Scoring Matrix. Curr Protoc Bioinformatics. 2013;43:351\u20139.","journal-title":"Curr Protoc Bioinformatics."},{"key":"1545_CR24","unstructured":"Gene Ontology C, Aleksander SA, Balhoff J, Carbon S, Cherry JM, Drabkin HJ, et al. The Gene Ontology knowledgebase in 2023. Genetics. 2023;224(1)."},{"issue":"10","key":"1545_CR25","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/bioinformatics\/btm087","volume":"23","author":"JZ Wang","year":"2007","unstructured":"Wang JZ, Du Z, Payattakool R, Yu PS, Chen CF. A new method to measure the semantic similarity of GO terms. Bioinformatics. 2007;23(10):1274\u201381.","journal-title":"Bioinformatics"},{"issue":"7","key":"1545_CR26","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/bioinformatics\/btq064","volume":"26","author":"G Yu","year":"2010","unstructured":"Yu G, Li F, Qin Y, Bo X, Wu Y, Wang S. GOSemSim: an R package for measuring semantic similarity among GO terms and gene products. Bioinformatics. 2010;26(7):976\u20138.","journal-title":"Bioinformatics"},{"issue":"3","key":"1545_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.26","volume":"10","author":"JM Banda","year":"2016","unstructured":"Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data. 2016;10(3): 160026.","journal-title":"Sci Data."},{"issue":"4","key":"1545_CR28","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/bcp.14762","volume":"88","author":"L Wang","year":"2022","unstructured":"Wang L, Shendre A, Chiang CW, Cao W, Ning X, Zhang P, et al. A pharmacovigilance study of pharmacokinetic drug interactions using a translational informatics discovery approach. Br J Clin Pharmacol. 2022;88(4):1471\u201381.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1545_CR29","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/amiajnl-2011-000116","volume":"18","author":"SJ Nelson","year":"2011","unstructured":"Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: RxNorm at 6 years. J Am Med Inform Assoc. 2011;18(4):441\u20138.","journal-title":"J Am Med Inform Assoc"},{"issue":"4","key":"1545_CR30","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1002\/cpt.1289","volume":"105","author":"L Lindstrom-Gommers","year":"2019","unstructured":"Lindstrom-Gommers L, Mullin T. International Conference on harmonization: recent reforms as a driver of global regulatory harmonization and innovation in medical products. Clin Pharmacol Ther. 2019;105(4):926\u201331.","journal-title":"Clin Pharmacol Ther."},{"issue":"6","key":"1545_CR31","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/jnci\/djh075","volume":"96","author":"S Wacholder","year":"2004","unstructured":"Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96(6):434\u201342.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1545_CR32","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1086\/519024","volume":"81","author":"J Wakefield","year":"2007","unstructured":"Wakefield J. A Bayesian measure of the probability of false discovery in genetic epidemiology studies. Am J Hum Genet. 2007;81(2):208\u201327.","journal-title":"Am J Hum Genet"},{"key":"1545_CR33","unstructured":"Side Effect Resource (SIDER 4.1). [cited; Available from: http:\/\/sideeffects.embl.de\/. Accessed 12 Jan 2024."},{"issue":"5","key":"1545_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2018.1","volume":"30","author":"D Demner-Fushman","year":"2018","unstructured":"Demner-Fushman D, Shooshan SE, Rodriguez L, Aronson AR, Lang F, Rogers W, et al. A dataset of 200 structured product labels annotated for adverse drug reactions. Sci Data. 2018;30(5): 180001.","journal-title":"Sci Data."},{"issue":"6","key":"1545_CR35","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1214\/aos\/1074290335","volume":"31","author":"JD Storey","year":"2003","unstructured":"Storey JD. The positive false discovery rate: a Bayesian interpretation and the q-value. Ann Stat. 2003;31(6):2013\u201335.","journal-title":"Ann Stat"},{"issue":"27","key":"1545_CR36","doi-asserted-by":"publisher","first-page":"5088","DOI":"10.1002\/sim.10216","volume":"43","author":"Y Shi","year":"2024","unstructured":"Shi Y, Eadon MT, Chen Y, Sun A, Yang Y, Chiang C, et al. A precision mixture risk model to identify adverse drug events in subpopulations using a case-crossover design. Stat Med. 2024;43(27):5088\u201399.","journal-title":"Stat Med"},{"key":"1545_CR37","unstructured":"Food and Drug Administration (FDA). Drug label of cabazitaxel. [cited; Available from: chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/201023lbl.pdf. Accessed 12 Jan 2024."},{"key":"1545_CR38","unstructured":"Food and Drug Administration (FDA). Drug label of iloperidone. [cited; Available from: chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022192lbl.pdf. Accessed 12 Jan 2024."},{"issue":"21","key":"1545_CR39","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2018.14276","volume":"320","author":"EC Goligher","year":"2018","unstructured":"Goligher EC, Tomlinson G, Hajage D, Wijeysundera DN, Fan E, Juni P, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc bayesian analysis of a randomized clinical trial. JAMA. 2018;320(21):2251\u20139.","journal-title":"JAMA"},{"issue":"3","key":"1545_CR40","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s43441-023-00515-3","volume":"57","author":"N Muehlemann","year":"2023","unstructured":"Muehlemann N, Zhou T, Mukherjee R, Hossain MI, Roychoudhury S, Russek-Cohen E. A tutorial on modern Bayesian methods in clinical trials. Ther Innov Regul Sci. 2023;57(3):402\u201316.","journal-title":"Ther Innov Regul Sci."},{"issue":"3","key":"1545_CR41","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3758\/s13428-018-01189-8","volume":"51","author":"AM Stefan","year":"2019","unstructured":"Stefan AM, Gronau QF, Schonbrodt FD, Wagenmakers EJ. A tutorial on Bayes Factor Design Analysis using an informed prior. Behav Res Methods. 2019;51(3):1042\u201358.","journal-title":"Behav Res Methods"},{"key":"1545_CR42","doi-asserted-by":"publisher","first-page":"25216","DOI":"10.3402\/ejpt.v6.25216","volume":"6","author":"R van de Schoot","year":"2015","unstructured":"van de Schoot R, Broere JJ, Perryck KH, Zondervan-Zwijnenburg M, van Loey NE. Analyzing small data sets using Bayesian estimation: the case of posttraumatic stress symptoms following mechanical ventilation in burn survivors. Eur J Psychotraumatol. 2015;6:25216.","journal-title":"Eur J Psychotraumatol"},{"issue":"5","key":"1545_CR43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40264-016-0392-2","volume":"39","author":"M Hauben","year":"2016","unstructured":"Hauben M, Aronson JK, Ferner RE. Evidence of misclassification of drug-event associations classified as gold standard \u201cnegative controls\u201d by the observational medical outcomes partnership (OMOP). Drug Saf. 2016;39(5):421\u201332.","journal-title":"Drug Saf"},{"issue":"Suppl 1","key":"1545_CR44","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1007\/s40264-013-0097-8","volume":"36","author":"PB Ryan","year":"2013","unstructured":"Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013;36(Suppl 1):S33-47.","journal-title":"Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01545-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01545-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01545-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T11:50:08Z","timestamp":1757159408000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01545-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1545"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01545-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"17 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by NIH (R01GM141279).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable. No human data were involved in this study. The Indiana University Institutional Review Board (IRB) designated this study as exempt.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"FAERS data are available from the US Food and Drug Administration (FDA, ). Optum\u2019s de-identified Clinformatics\u00ae Data Mart Database is available from Optum (optum.com). SIDER data is available from SIDER 4.1: Side Effect Resource (). Data from Demner-Fushman et al. is available form doi: . Summary statistics generated during this study are included in this published article and its supplementary files.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Model codes are provided in the Online Supplementary files and GitHub ().","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"PeZ and PiZ conceived the study; YS, YY, RL, AS and XP conducted data analysis; YS, YY, PeZ and PiZ drafted the manuscript. All authors interpreted the results, critically revised, and gave final approval of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}